作者：
Raymone,Pajarillo [1]
;
Luca,Paruzzo [1]
;
Alberto,Carturan [2]
;
Ositadimma,Ugwuanyi [2]
;
Griffin,White [3]
;
Puneeth,Guruprasad [2]
;
Hatcher J,Ballard [3]
;
Ruchi P,Patel [2]
;
Yunlin,Zhang [2]
;
Yong Gu,Lee [4]
;
Seok Jae Albert,Hong [2]
;
Gregory M,Dittami [5]
;
Marco,Ruella [6]
作者单位：
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
[1]
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
[2]
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
[3]
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.
[4]
ORFLO Technologies, Ketchum, Idaho, USA.
[5]
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: mruella@upenn.edu.
[6]
DOI
10.1016/j.jcyt.2024.01.007
PMID
38483365
发布时间
2024-07-20
换一批
换一批
